[Sisa Today, Reporter Haewon Jeon] We go to the hospital because we are, so to speak, 'in pain.' The goal is to identify the cause of 'pain' — the body's distress signal — and receive appropriate treatment. However, 慢性疼痛 that follows like a shadow even after recovery from illness endlessly torments patients and plunges them into suffering.
The 世界卫生组织 (WHO) classifies such 慢性疼痛 not as a byproduct of illness but as a 'disease' in its own right. In other words, 'pain' is not just a symptom but a condition that requires treatment.
CEO Yongho Kim of RudaCure Inc. (www.rudacure.com), an assistant professor in the Department of Physiology at 嘉泉大学医学院, has dedicated himself to fundamental research on 'pain' that goes beyond conventional 疼痛缓解 concepts, stepping up to present a new paradigm for 韩国's 新药开发 industry.
The company's diversified business areas include ▲ CRPS (Complex Regional Pain Syndrome) ▲ 神经性疼痛 ▲ cancer-induced pain ▲ 眼部 diseases (干眼症, 黄斑变性), and the company is developing solutions in all these areas.